Premium
Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients
Author(s) -
Jin T.,
Hu L.S.,
Chang M.,
Wu J.,
Winblad B.,
Zhu J.
Publication year - 2007
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2007.01761.x
Subject(s) - pathogenesis , cerebrospinal fluid , medicine , haptoglobin , proteome , apolipoprotein b , transthyretin , proteomics , disease , apolipoprotein e , immunology , multiple sclerosis , guillain barre syndrome , pathology , biology , bioinformatics , gene , biochemistry , cholesterol
Increased protein level in the cerebrospinal fluid (CSF) is a characteristic of patients with Guillain–Barré syndrome (GBS), an acute inflammatory autoimmune disorder in the peripheral nervous system (PNS). However, the molecular mechanisms underlying the disease remain poorly understood and so far no reliable disease‐related markers are available. By comparing the CSF proteome of GBS patients with control subjects suffering from other neurological disorders, it may be possible to identify proteins that involve in the disease process and thus to study the pathogenesis of GBS. We used two‐dimensional difference gel electrophoresis (2D DIGE) technique, in combination with matrix‐assisted laser desorption ionization time of flight mass spectrometry (MALDI‐TOF MS), to determine the abnormal CSF proteins in GBS patients. Our data showed that the levels of six proteins and their isoforms in CSF were significantly altered in GBS patients compared with controls. Haptoglobin, apolipoprotein A‐IV and PRO2044 (unnamed protein) were considerably increased in the CSF of GBS patients, whereas transthyretin, apolipoprotein E and fibrinogen were considerably decreased. We concluded that these six proteins may be involved in the pathogenesis of GBS and call for further studying the role of these proteins in the pathogenesis of the disease.